November 14, 2023 10:38 AM EST

FDA touts new authority as ODAC hosts adcomm to review delayed confirmatory trials for accelerated approvals

Zachary Brennan

Senior Editor

The FDA’s Oncologic Drugs Advisory Committee will meet Thursday to look at two cancer drugs that first won accelerated approval in 2009 and 2014 but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA touts new authority as ODAC hosts adcomm to review delayed confirmatory trials for accelerated approvals

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

FDA touts new au­thor­i­ty as ODAC hosts ad­comm to re­view de­layed con­fir­ma­to­ry tri­als for ac­cel­er­at­ed ap­provals

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

FDA touts new authority as ODAC hosts adcomm to review delayed confirmatory trials for accelerated approvals

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?